Liquidia Corp
NASDAQ:LQDA

Watchlist Manager
Liquidia Corp Logo
Liquidia Corp
NASDAQ:LQDA
Watchlist
Price: 10.65 USD 4.93% Market Closed
Market Cap: 894.6m USD
Have any thoughts about
Liquidia Corp?
Write Note

Liquidia Corp
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Liquidia Corp
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Liquidia Corp
NASDAQ:LQDA
Cash from Financing Activities
$132.6m
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Financing Activities
-$6.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Financing Activities
$7.7B
CAGR 3-Years
N/A
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Cash from Financing Activities
-$5.7B
CAGR 3-Years
34%
CAGR 5-Years
14%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Cash from Financing Activities
-$6.3B
CAGR 3-Years
-72%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash from Financing Activities
$5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Liquidia Corp
Glance View

Market Cap
813.8m USD
Industry
Pharmaceuticals

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.

LQDA Intrinsic Value
5.84 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Liquidia Corp's Cash from Financing Activities?
Cash from Financing Activities
132.6m USD

Based on the financial report for Jun 30, 2024, Liquidia Corp's Cash from Financing Activities amounts to 132.6m USD.

What is Liquidia Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
10%

Over the last year, the Cash from Financing Activities growth was 1 234%. The average annual Cash from Financing Activities growth rates for Liquidia Corp have been 13% over the past three years , 10% over the past five years .

Back to Top